Kidney Failure Xanthine Oxidase. Febuxostat is a novel nonpurine xanthine oxidase xo specific inhibitor for treating hyperuricemia. Although xanthine oxidase xo inhibitors are expected to protect the kidney function evidence to this end is insufficient at present.
Pathophysiology Of Acute Renal Failure Following Tumor Lysis Syndrome Download Scientific Diagram from www.researchgate.net
Hyperuricemia is a known risk factor for end stage renal disease. Febuxostat is a novel nonpurine xanthine oxidase xo specific inhibitor for treating hyperuricemia. Renal interstitial fibrosis is the common pathway in progressive renal diseases where oxidative stress promotes inflammation and macrophage infiltration.
To assess the effects of xanthine oxidase xo inhibition on ischemic injury rats were pretreated with oxypurinol oxy 5 mg kg and subjected to 30 min of bilateral renal artery occlusion.
Hyperuricemia is a known risk factor for end stage renal disease. Oxy s effect on adenine nucleotide nucleoside purine base concentrations was determined at 10 and 30 min of ischemia and during reperfusion 5 and 30 min. However asymptomatic and therefore undiagnosed stones may invade the kidney and urinary tract resulting in destruction of parenchyma nephrectomy and renal failure. Hyperuricemia is a known risk factor for end stage renal disease.
